反应详情

To a stirred solution of N-tert-butyl-2-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-7-yl)-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide (120 mg, 0.258 mmol) in dioxane (20 mL) was bubbled HCl gas until saturation and the reaction stirred at room temperature for 16 hours. Reaction mixture was concentrated and the residue purified by preparative-HPLC (Gemini 5u C18 150×21.2 mm; inject volume: 3 mL/inj, flow rate: 20 mL/min; wavelength: 214 nm and 254 nm; the gradient conditions are: 40% acetonitrile/60% water (0.1% trifluoroacetic acid V/V) initially, and then proceed to 50% acetonitrile/50% water (0.1% trifluoroacetic acid V/V) in a linear fashion after just 9 min.). Concentrated HCl was added to the combined fractions containing pure product, then solvents evaporated to afford N-tert-butyl-2-(1H-indazol-7-yl)-5H-pyrrolo[3,2-b]pyrazine-7-carboxamide hydrochloride (20 mg, 21%) as a yellow solid. LCMS: (M+H)+=335; 1H NMR (300 MHz, CD3OD): δ 8.94 (s, 1H), 8.34 (s, 1H), 8.31 (s, 1H), 7.97 (s, 1H), 7.94 (s, 1H), 7.39 (t, 1H, J=6.9 Hz), 1.52 (s, 9H).

1. customReaction mixture
2. concentrationwas concentrated
3. customthe residue purified by preparative-HPLC (Gemini 5u C18 150×21.2 mm
4. wait40% acetonitrile/60% water (0.1% trifluoroacetic acid V/V) initially, and then proceed to 50% acetonitrile/50% water (0.1% trifluoroacetic acid V/V) in a linear fashion after just 9 min.
5. additionConcentrated HCl was added to the combined fractions
6. additioncontaining pure product
7. customsolvents evaporated